Express News | Aclaris Therapeutics Appoints Jesse Hall, M.d. as Chief Medical Officer
Press Release: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Strong Week for Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Doesn't Alleviate Pain of Three-year Loss
Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2
Express News | Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody
Aclaris Therapeutics Assumed With an Overweight at Cantor Fitzgerald
Cantor Fitzgerald Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight
Scotiabank Initiates Coverage On Aclaris Therapeutics With Sector Outperform Rating, Announces Price Target of $15
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Cuts Target Price to $2
Express News | Aclaris Therapeutics Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing
Aclaris Therapeutics | 10-K: FY2024 Annual Report
Express News | Aclaris Therapeutics Expects Cash Runway Into 2028
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Reports Q4 EPS ($1.01), Consensus (38c)
Express News | Aclaris Therapeutics Q4 Net Income USD -96.552 Million Vs. IBES Estimate USD -22.4 Million